---
title: "Passage Bio, Inc. (PASG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PASG.US.md"
symbol: "PASG.US"
name: "Passage Bio, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T19:26:58.841Z"
locales:
  - [en](https://longbridge.com/en/quote/PASG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PASG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PASG.US.md)
---

# Passage Bio, Inc. (PASG.US)

## Company Overview

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.passagebio.com](https://www.passagebio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.44 | 126 | - | - | - |
| PB | 1.42 | 127 | 1.21 | 0.78 | 0.57 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 25% |
| Hold | 3 | 75% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.22 |
| Highest Target | 23.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PASG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PASG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PASG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PASG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**